Regenerative Biologics
in Reproductive
Medicine

Asherman’s syndrome — intrauterine adhesions following curettage, myomectomy, cesarean section, or severe endometritis — is graded by the American Fertility Society (AFS) classification from minimal (Grade I, filmy adhesions) to severe (Grade III, dense bands obliterating the cavity). Hysteroscopic adhesiolysis is the standard treatment, but re-adhesion rates are high: 3–30% for mild disease and 40–66% for severe cases with conventional post-operative management.

Amniotic membrane placement after adhesiolysis has a specific and well-evidenced role: the Amer 2013 RCT demonstrates 22% vs. 58% re-adhesion rates with amniotic membrane coverage at second-look hysteroscopy, with significantly better endometrial thickness and clinical pregnancy outcomes. For severe Asherman’s with endometrial atrophy (the most challenging clinical scenario), WJ-MSC intrauterine infusion provides the biological depth to support endometrial regeneration — the Alawadhi 2019 series shows measurable endometrial thickness improvement and 64% menstrual return in this difficult-to-treat population.

Diminished ovarian reserve (DOR) — defined by AMH <1.1 ng/mL and/or AFC <5–7 on transvaginal ultrasound — is the most common biologic indication driving patient interest in ovarian PRP. The clinical impact is profound: poor ovarian responders in IVF yield fewer oocytes, have higher cycle cancellation rates, and lower live birth rates than normal responders.

Ovarian PRP has the most active research landscape of any reproductive biologic application — with over 25 prospective studies and multiple ongoing RCTs as of 2024. The strongest observational signal is AMH improvement (seen in 40–60% of patients at 3 months) and AFC increase. The clinical endpoint that matters — live birth after autologous IVF — is improving in prospective series but has not been demonstrated in an adequately powered Phase III RCT. Practitioners offering ovarian PRP should communicate clearly: it is a biologically rational, clinically studied intervention showing meaningful signals, but not yet standard of care, and outcomes are not guaranteed.

Premature ovarian insufficiency (POI) — defined as ovarian failure before age 40 with FSH >25 IU/L on two measurements ≥4 weeks apart — affects approximately 1% of women under 40 and 0.1% under 30. Unlike menopause, POI has intermittent residual ovarian function in up to 50% of cases, meaning occasional follicle activation and even spontaneous pregnancy can occur. This residual activity is the theoretical target for ovarian PRP — amplifying the intermittent follicular activity that remains.

The Hsieh 2020 series is the most representative POI data — 35% resumed menstruation, 30% measurable AMH, 15% oocyte retrieval, 10% clinical pregnancy — with the important observation that early POI (<24 months duration) responds better than long-standing POI. For patients with complete, long-standing ovarian failure (FSH >40 IU/L, AMH undetectable for >3–4 years), the biological basis for response is much weaker and expectations should be calibrated accordingly. Patient communication: this is not a cure for POI; it is an investigation-level intervention with meaningful but modest response rates.

Recurrent implantation failure (RIF) — typically defined as failure to achieve clinical pregnancy after ≥3 IVF embryo transfers with good-quality embryos — is a diagnosis of exclusion that remains unexplained after standard investigation in many cases. Endometrial, embryonic, and immunological factors all contribute in different proportions in different patients. The heterogeneity of the RIF population is the major challenge for biologic trial design and interpretation.

The Nazari 2019 RCT is the most important data point for reproductive PRP — the first adequately powered, randomized, controlled trial in any reproductive biologic indication, demonstrating significantly higher clinical pregnancy rates (53.1% vs. 33.3%) and live birth rates (47.9% vs. 29.2%) with PRP vs. saline infusion. The NK cell reduction on biopsy supports the immunomodulatory mechanism. This data represents a genuine clinical advance, but replication in independent multicenter trials is required before PRP for RIF becomes standard of care.

Non-obstructive azoospermia — the absence of sperm in the ejaculate due to testicular failure rather than obstruction — affects approximately 1% of men and 10% of infertile men. It is the most severe form of male factor infertility. Microsurgical sperm extraction (micro-TESE) can retrieve sperm for ICSI in 40–60% of cases, but the procedure requires a viable spermatogenic focus in the testis.

Intratesticular PRP injection prior to micro-TESE has been evaluated as a method of improving the spermatogenic microenvironment before sperm retrieval — the hypothesis being that VEGF improves testicular microcirculation, IGF-1 and EGF support Sertoli cell function, and PDGF activates spermatogonial stem cells. Phase I/II series report improved micro-TESE sperm retrieval rates in PRP-pretreated patients vs. historical controls, though the absence of randomized controlled data makes definitive efficacy conclusions premature. This is a meaningful application for the most treatment-refractory male infertility subgroup.

Vasculogenic erectile dysfunction — ED arising from impaired cavernosal arterial inflow or venous leakage rather than psychogenic or hormonal causes — affects the majority of organic ED cases. PDE5 inhibitors (sildenafil, tadalafil) manage symptoms by potentiating nitric oxide vasodilation but do not address the underlying endothelial dysfunction and vascular pathology. Biologic approaches target the structural vascular deficit through cavernosal angiogenesis.

Penile PRP injection (the “P-Shot” protocol, intracavernosal injection of 5–10 mL PRP) has been evaluated in multiple prospective series. A systematic review (Kalyvianakis 2017) identified 5 prospective studies showing significant IIEF score improvements at 3–6 months, with the most consistent benefit in mild-to-moderate vasculogenic ED. BMAC injection (Bahk 2010) provides greater biological depth but requires iliac crest harvest. The mechanism — VEGF-driven cavernosal neoangiogenesis and NGF-mediated cavernous nerve support — is biologically plausible and consistent with the observed response pattern.

Peyronie’s disease — penile fibrosis producing a collagenous plaque in the tunica albuginea, causing pain, curvature, and erectile dysfunction — affects 3–9% of men. The active phase (plaque forming, painful, progressive curvature) versus stable phase distinction determines treatment timing: active phase intervention aims to arrest plaque formation; stable phase intervention targets established plaque resolution.

Intralesional PRP injection has been evaluated for Peyronie’s disease as an alternative or adjunct to collagenase (Xiaflex, the only FDA-approved intralesional treatment). PRP’s MMP upregulation and anti-fibrotic mechanisms may reduce plaque collagen density and associated curvature. Prospective series (Virag 2015) report significant improvements in PDQ scores and curvature angles in PRP-treated patients at 6 months, with an acceptable safety profile. Combination with penile traction therapy enhances outcomes in comparative series. FDA clearance exists for collagenase; PRP is off-label for this indication.